WATER SOLUBLE ADJUVANT AND COMPOSITION CONTAINING SAME
The present invention relates to a compound useful as a vaccine adjuvant for cancer vaccine, a preparation process thereof, a pharmaceutical composition comprising the compound, and use of the compound as a vaccine adjuvant for cancer vaccine.
1 . A compound of formula (1):
or a pharmaceutically acceptable salt thereof, wherein
X is single bond, oxygen atom, sulfur atom, SO, SO 2 , or NR 6 wherein R 6 is hydrogen atom or C 1-6 alkyl,
R 1 is C 1-6 alkyl which may be substituted with 1-5 substituents selected independently from the group consisting of halogen, hydroxy, and C 1-6 alkoxy,
R 2 is hydrogen atom, halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy or cyano,
m is an integer of 1-5,
A is 5- to 8-membered monocyclic aromatic carbon ring or 4- to 7-membered monocyclic aromatic hetero ring,
L is a linker, and
Y 1 is —(CH 2 CH 2 O) n —R 3 , wherein R 3 is hydrogen atom or C 1-6 alkyl, and n is an integer of 3-100,
provided that the compound having the following structure is excluded
2 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein X is single bond, oxygen atom, or NR 6 .
3 . The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein X is single bond or oxygen atom.
4 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 1 is C 1-6 alkyl which may be substituted with 1-3 the same or different C 1-6 alkoxy.
5 . The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein R 1 is C 1-6 alkyl which may be substituted with one C 1-6 alkoxy.
6 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen atom, halogen, C 1-6 alkyl, or C 1-6 alkoxy.
7 . The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein R 2 is hydrogen atom or halogen.
8 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein m is 1.
9 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein A is benzene ring or pyridine ring.
10 . The compound of claim 9 or a pharmaceutically acceptable salt thereof, wherein A is pyridine ring.
11 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein
L is —O—, —NR Y —, —C(O)—, —C(O)O—, —OC(O)—, —C(O)NR Y —, —NR Y C(O)—, —CH 2 NR Y —, —CH 2 O—, —OC(O)O—, —NR 4 C(O)O—, —OC(O)NR Y —, —NR 4 C(O)NR Y —, —OC(S)NR Y —, or —NR 4 C(S)NR Y —, wherein R 4 is hydrogen atom or C 1-6 alkyl, and R Y is hydrogen atom, C 1-6 alkyl or Y 2 , wherein Y 2 is —(CH 2 CH 2 O) p —R 5 , R 5 is hydrogen atom or C 1-6 alkyl, and p is an integer of 3-100.
12 . The compound of claim 11 or a pharmaceutically acceptable salt thereof, wherein L is —CH 2 NR Y —.
13 . (canceled)
14 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein Y 1 is —(CH 2 CH 2 O) n —R 3 wherein n is an integer of 3-40, and R 3 is hydrogen atom or C 1-6 alkyl.
15 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is a compound of formula (2):
or formula (3):
wherein
R 1 is C 1-6 alkyl which may be substituted with one C 1-6 alkoxy,
L is —CH 2 NR Y — wherein R Y is hydrogen atom or C 1-6 alkyl,
Y 1 is —(CH 2 CH 2 O) n —R 3 , R 3 is hydrogen atom or C 1-6 alkyl, and n is an integer of 3-40.
16 . The compound of claim 1 or a pharmaceutically acceptable salt thereof, which is selected from:
6-amino-2-butoxy-9-{[5-(16-hydroxy-2-methyl-5,8,11,14-tetraoxa-2-azahexadecan-1-yl)pyridin-2-yl]methyl}-7,9-dihydro-8H-purin-8-one,
6-amino-2-butoxy-9-{[6-(16-hydroxy-2-methyl-5,8,11,14-tetraoxa-2-azahexadecan-1-yl)pyridin-3-yl]methyl}-7,9-dihydro-8H-purin-8-one,
6-amino-2-butoxy-9-{[4-(16-hydroxy-2-methyl-5,8,11,14-tetraoxa-2-azahexadecan-1-yl)phenyl]methyl}-7,9-dihydro-8H-purin-8-one,
6-amino-9-{[4-(16-hydroxy-2-methyl-5,8,11,14-tetraoxa-2-azahexadecan-1-yl)phenyl]methyl}-2-(2-methoxyethoxy)-7,9-dihydro-8H-purin-8-one,
6-amino-2-butoxy-9-({6-[13-hydroxy-2-(2-{2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}ethyl)-5,8,11-trioxa-2-azatridecan-1-yl]pyridin-3-yl}methyl)-7,9-dihydro-8H-purin-8-one,
6-amino-2-butoxy-9-{[6-(31-hydroxy-2-methyl-5,8,11,14,17,20,23,26,29-nonaoxa-2-azahentriacontan-1-yl)pyridin-3-yl]methyl}-7,9-dihydro-8H-purin-8-one,
6-amino-2-butoxy-9-{[6-(73-hydroxy-2-methyl-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71-tricosaoxa-2-azatriheptacontan-1-yl)pyridin-3-yl]methyl}-7,9-dihydro-8H-purin-8-one, and
6-amino-2-butoxy-9-{[6-(109-hydroxy-2-methyl-5,8,11,14,17,20,23,26,29,32,35,38,41,44,47,50,53,56,59,62,65,68,71,74,77,80,83,86,89,92,95,98, 101,104,107-pentatriacontaoxa-2-azanonahectan-1-yl)pyridin-3-yl]methyl}-7,9-dihydro-8H-purin-8-one.
17 . A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient, and a pharmaceutically acceptable carrier.
18 . The pharmaceutical composition of claim 17 , which is an emulsion formulation.
19 . The pharmaceutical composition of claim 18 , wherein the emulsion formulation is a water-in-oil emulsion.
20 . The pharmaceutical composition of claim 19 , wherein the emulsion formulation comprises (1) ethyl oleate, octyldodecyl myristate, sorbitan monooleate, glyceryl monooleate, polyoxyethylene hydrogenated castor oil 20, glycerin, and sodium dihydrogen phosphate, or (2) Montanide ISA 51VG.
21 . The pharmaceutical composition of claim 17 , which further comprises a tumor antigen.
22 . The pharmaceutical composition of claim 21 , wherein the tumor antigen is a tumor antigen peptide.
23 . The pharmaceutical composition of claim 22 , wherein the tumor antigen peptide is a combination of a peptide represented by the amino acid sequence of formula (4):
wherein the bond between C—C is disulfide bond, or a pharmaceutically acceptable salt thereof, and
a peptide represented by the amino acid sequence of SEQ ID NO 3: WAPVLDFAPPGASAYGSL, or a pharmaceutically acceptable salt thereof.
24 . A vaccine adjuvant for cancer vaccine comprising a compound of formula (1):
or a pharmaceutically acceptable salt thereof, wherein
X is single bond, oxygen atom, sulfur atom, SO, SO 2 , or NR 6 wherein R 6 is hydrogen atom or C 1-6 alkyl,
R 1 is C 1-6 alkyl which may be substituted with 1-5 substituents selected independently from the group consisting of halogen, hydroxy, and C 1-6 alkoxy,
R 2 is hydrogen atom, halogen, hydroxy, C 1-6 alkyl, C 1-6 alkoxy or cyano,
m is an integer of 1-5,
A is 5- to 8-membered monocyclic aromatic carbon ring or 4- to 7-membered monocyclic aromatic hetero ring,
L is a linker, and
Y 1 is —(CH 2 CH 2 O) n —R 3 , wherein R 3 is hydrogen atom or C 1-6 alkyl, and n is an integer of 3-100.
25 . A kit comprising:
a) the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
b) a tumor antigen or a pharmaceutical composition comprising a tumor antigen.
26 . The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein L is —O—, —NR Y —, —C(O)—, —C(O)O—, —OC(O)—, —C(O)NR Y —, —NR Y C(O)—, —CH 2 NR Y —, —CH 2 O—, —OC(O)O—, —NR 4 C(O)O—, —OC(O)NR Y —, —NR 4 C(O)NR Y —, —OC(S)NR Y —, or —NR 4 C(S)NR Y —, wherein R 4 is hydrogen atom or C 1-6 alkyl, and R Y is hydrogen atom, C 1-6 alkyl or Y 2 wherein Y 2 is —(CH 2 CH 2 O) p —R 5 , wherein R 5 is hydrogen atom or C 1-6 alkyl, and p is an integer of 3-100.
27 . The pharmaceutical composition of claim 17 , which is a lipid formulation.
28 . The pharmaceutical composition of claim 27 , wherein the lipid formulation is a liposome formulation comprising phospholipid.
29 . The pharmaceutical composition of claim 27 , wherein the lipid formulation is a liposome formulation comprising sterols.
30 . The pharmaceutical composition of claim 29 , wherein the sterols is cholesterol.
31 . The pharmaceutical composition of claim 27 , wherein the liposome formulation comprises at least one additive selected from the group consisting of inorganic acid, inorganic acid salt, organic acid, organic acid salt, sugars, buffering agent, antioxidant, and polymers.
32 . A method for inducing CTL in mammal, comprising administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to the mammal.
33 . A method for enhancing the CTL induction in mammal, comprising administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to the mammal.
34 . A method for enhancing specific immune response in mammal to an antigen, comprising administering the compound of claim 1 or a pharmaceutically acceptable salt thereof to the mammal.
35 . A kit comprising:
a) the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
b) an antigen or a pharmaceutical composition comprising an antigen.
36 . A kit comprising:
a) the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
b) a pathogen-derived antigen or a pharmaceutical composition comprising a pathogen-derived antigen.
37 . A kit comprising:
a) a pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
b) a tumor antigen or a pharmaceutical composition comprising a tumor antigen.
38 . A kit comprising:
a) a pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
b) an antigen or a pharmaceutical composition comprising an antigen.
39 . A kit comprising:
a) a pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof; and
b) a pathogen-derived antigen or a pharmaceutical composition comprising a pathogen-derived antigen.